MicroRNA molecules are becoming increasingly interesting for research, as they are involved in numerous physiological and pathological processes in the body, including bone remodelling. Disrupted bone remodelling leads to various diseases, including osteoporosis. Previous studies conducted at the Department of Clinical Biochemistry identified altered expression of hsa-miR-20b-5p in connection with osteoporosis treatment. The aim of this thesis was to identify and experimentally confirm the target genes of this microRNA. Based on bioinformatic analysis, we selected genes FZD3 and BMPR2. We designed oligonucleotides containing the binding site for hsa-miR-20b-5p, based on the nucleotide sequences in the mRNA of the target genes. In addition to the target sequences, we also designed a sequence for a positive control, which was a complementary sequence to the microRNA. This was followed by an optimization of the process for inserting the oligonucleotides into the pmirGLO plasmid. The entire process included plasmid restriction, agarose gel electrophoresis, ligation of the oligonucleotides into the digested plasmid, and transformation of Top10 cells with the recombinant plasmid. The prepared plasmids were then transfected into two mammalian cell lines (HOS and HeLa). A dual-luciferase reporter assay was performed on these cells. We measured firefly and Renilla luciferase activity. These values were normalized by calculating their ratio, and the data were subsequently analyzed using the statistical software SPSS. We found that hsa-miR-20b-5p bound to the sequences of FZD3 and BMPR2 in the HeLa cell line, confirming their direct interaction. In the HOS cell line, there were no statistically significant differences between any of the sample pairs, most likely due to inefficient transfection, which would need to be optimized in future experiments. The confirmed binding of hsa-miR-20b-5p to these two genes could serve as a basis for developing new therapeutic strategies for conditions where suppression of bone formation is desired (e.g., bone cancer). Conversely, inhibiting this interaction might provide novel therapeutic options for treating osteoporosis.
|